Like its marketed lupus treatment Benlysta belimumab, many of the clinical programs at Human Genome Sciences Inc. (NASDAQ:HGSI) are partnered with suitor GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Non-GSK programs include anthrax treatment raxibacumab, which HGS is developing under a contract with the Biomedical Advanced Research and Development Authority